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BACKGROUND: Guidelines underline the role of individual preferences in the selection of a screening test, as insufficient evidence is
available to recommend one screening test over another. We conducted a study to determine the preferences of individuals and to
predict uptake for colorectal cancer (CRC) screening programmes using various screening tests.
METHODS: A discrete choice experiment (DCE) questionnaire was distributed among naive subjects, yet to be screened, and
previously screened subjects, aged 50–75 years. Subjects were asked to choose between scenarios on the basis of faecal occult
blood test (FOBT), flexible sigmoidoscopy (FS), total colonoscopy (TC) with various test-specific screening intervals and mortality
reductions, and no screening (opt-out).
RESULTS:In total, 489 out of 1498 (33%) screening-naı ¨ve subjects (52% male; mean age±s.d. 61±7years) and 545 out of 769 (71%)
previously screened subjects (52% male; mean age±s.d. 61±6years) returned the questionnaire. The type of screening test,
screening interval, and risk reduction of CRC-related mortality influenced subjects’ preferences (all Po0.05). Screening-naive and
previously screened subjects equally preferred 5-yearly FS and 10-yearly TC (P¼0.24; P¼0.11), but favoured both strategies to
annual FOBT screening (all P-values o0.001) if, based on the literature, realistic risk reduction of CRC-related mortality was applied.
Screening-naive and previously screened subjects were willing to undergo a 10-yearly TC instead of a 5-yearly FS to obtain an
additional risk reduction of CRC-related mortality of 45% (Po0.001).
CONCLUSION: These data provide insight into the extent by which interval and risk reduction of CRC-related mortality affect
preferences for CRC screening tests. Assuming realistic test characteristics, subjects in the target population preferred endoscopic
screening over FOBT screening, partly, due to the more favourable risk reduction of CRC-related mortality by endoscopy screening.
Increasing the knowledge of potential screenees regarding risk reduction by different screening strategies is, therefore, warranted to
prevent unrealistic expectations and to optimise informed choice.
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Colorectal cancer (CRC) is the second leading cause of cancer-
related deaths in the Western world. Screening can reduce CRC-
related mortality by removal of adenomas and early detection of
CRC (Newcomb et al,1 9 9 2 ;S e l b yet al, 1992; Mandel et al, 1993;
Hardcastle et al, 1996; Kronborg et al, 1996). There is compelling
evidence to support screening of average-risk individuals aged over
50 years (Mandel et al, 1993; Kewenter et al, 1994; Hardcastle et al,
1996; Kronborg et al, 1996; Hoff et al, 2009). Guidelines underline
the role of individual preferences in the selection of a screening test
(Council Recommendation on Cancer Screening, 2003; Levin et al,
2008; Sung et al, 2008), as insufficient evidence is available to
recommend one screening test over another. Individual preferences
for a certain screening test have been found to influence uptake in a
CRC-screening programme (Wolf et al, 2006). Uptake is a key factor
that determines the effectiveness of such a screening program.
However, uptake levels are fairly low in many countries (o60%)
(Hardcastle et al, 1996; Kronborg et al, 1996; Segnan et al,2 0 0 2 ;U K
Flexible Sigmoidoscopy Screening Investigators, 2002; van Rossum
et al, 2008; Hol et al, 2009a). Several countries, including The
Netherlands, are presently considering to introduce a nation-wide
CRC-screening program. It is therefore essential to obtain insight
into individual preferences for available screening strategies before
the implementation of a nation-wide screening programme.
Previous surveys have demonstrated a broad variation in
preferences for CRC screening tests, as tests differ in benefit
(CRC mortality reduction) on the one hand and potential harms on
the other hand (perceived burden and complications). Subjects
who valued effectiveness most highly chose colonoscopy screening,
whereas others preferred faecal occult blood testing (FOBT)
because of its less invasive nature (Pignone et al, 1999;
Frew et al, 2005; Wolf et al, 2006; DeBourcy et al, 2008). These
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sstudies, however, did not provide data on the relative importance
of test characteristics on preferences; for example, how much
potential health gain does a subject require to undergo invasive
endoscopic screening?
Discrete choice experiments (DCEs) are becoming more widely
used in health-care research (Gyrd-Hansen and Sogaard, 2001;
Sculpher et al, 2004; Marshall et al, 2007, 2009; Hur et al, 2008). A
DCE is capable of establishing preferences and to predict uptake in
controlled experimental conditions, through responses to realistic
and hypothetical scenarios. The DCEs may be valuable for patient-
centred evaluations of health technologies (Ryan, 2004).
This study was conducted to determine individuals’ preferences
and to predict the uptake of CRC screening programmes with
various screening tests, and the relative importance of different
test characteristics for these preferences in an average-risk
population. Furthermore, we aimed to identify the differences in
preference structures among subgroups in the population.
MATERIALS AND METHODS
Study population
A total of 1498 screening-naive individuals, aged 50–74 years, were
randomly selected from municipal registries of the Rotterdam
region in the southwest of the Netherlands. We also invited a
random sample of 769 screened subjects of a CRC screening trial
comparing guaiac-based FOBT (gFOBT), faecal immunochemical
test (FIT) and flexible sigmoidoscopy (FS; Figure 1). This screening
trial was carried out in the same target population as mentioned
above (Hol et al, 2009a). Age, sex and social economic status were
found to be equally distributed among the screening-naive and
previously screened invitees.
Discrete choice experiments
The DCEs can measure individuals’ preferences for health-care
interventions. The DCEs are based on the assumptions that a
health-care intervention can be described by its characteristics
(attributes) (e.g. frequency of undergoing the intervention) and
that the individual valuation of the intervention is determined by
pre-defined levels (e.g. monthly or yearly) of those attributes. The
health-care intervention (e.g. screening test) and its test char-
acteristics have to be specified before generating an experimental
design. In a DCE, individuals choose between several realistic and
hypothetical scenarios. Preference estimates can be obtained from
the choice data and describe the relative preference for character-
istics of the health-care intervention.
Attributes and levels
Tests such as FOBT, FS and total colonoscopy (TC) are most widely
used as CRC screening tests and, therefore, are incorporated in this
study design. The characteristics and their levels were derived from
the literature, expert opinions (n¼3) and interviews with potential
screenees (n¼40). Experts were asked to comment on a list of
characteristics derived from literature review. Potential screenees
could also comment on the list of characteristics and rank them in
the order of importance. On the basis of these data, we selected the
two most important characteristics as identified by both groups: risk
reduction of CRC-related mortality (RR) and screening interval.
Notably, characteristics that are related directly to the test (e.g. oral
bowel cleansing solution is not required for FOBT and always for
TC) were already captured by the specific screening test (FOBT, FS
and TC). All subjects were informed regarding the incorporated test
characteristics of the three screening tests (Table A2). The specific
values (levels; e.g. amount of risk reduction or length of screening
interval) for each test characteristic incorporated the range of
possible test outcomes of a specific screening test (FOBT, FS and
TC) based on the current literature (Table 1). The levels were test-
specific to create realistic scenarios (Table 1). Levels of RR were
presented in the questionnaire as absolute values to reduce framing
effects, in accordance to the literature (Edwards et al, 2002). In the
presentation of the results in this paper, we used the relative risk on
CRC-related death, as this is most commonly used in the screening
literature (e.g. FOBT: 13–18% RR). The absolute risk of CRC-related
death without screening was set at 3.0%. People aged 50 years in the
Netherlands have a 3.0% risk of dying from CRC, based on data
from the Dutch comprehensive cancer centre (IKC, www.ikc.nl).
Study design and questionnaire
The design contained three tests (FOBT, FS and TC) and two
characteristics (RR of CRC-related mortality and screening
interval) with three levels each (Table 1). The test-specific levels
(e.g. screening interval of FOBT between 4 months and triennial)
were required to select realistic combinations. Furthermore,
unrealistic combinations of the characteristics’ levels were blocked
(i.e. a combination of the lowest RR with the shortest screening
interval and the highest RR combined with the longest screening
interval). The combination of the characteristics and levels
resulted in 21 (i.e. 7 3) possible test scenarios, and thus 343
(i.e. 7
3) possible combinations of scenarios (i.e. full factorial
design). It is not feasible to present a single individual with all
these combinations. We therefore reduced the design in such away
that two-way interactions could be estimated (i.e. we created a
fractional factorial design). We therefore used SAS software (Version
Screening-naive Screened
1498 were invited
400 (82%) analysable
1009 did not respond
489 (33%) responded
769 were invited
496 (91%) analysable
545 (71%) responded
89 failed the
rationality test
224 did not respond
49 failed the
rationality test
257 FS
participants
256 gFOBT
participants
256 FIT
participants
Figure 1 Study profile. gFOBT¼guaiac-based faecal occult blood test; FIT¼immunochemical faecal occult blood test; FS¼flexible sigmoidoscopy.
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s9.1, SAS Institute, Cary, NC, USA) that is capable of generating
designs that are highly efficient (i.e. maximising D-efficiency or
minimising D-error) in such circumstances (Street et al,2 0 0 5 ) .W e
chose a design with 84 choice sets divided over seven versions of the
questionnaire (D-error: 0.573). Each choice set included two CRC
screening tests and an option of not to be screened (opt-out;
Table A1). A design in which all three screening tests and the option
not to be screened were presented in one scenario was not feasible, as
the pilot study (n¼20) showed a significant decrease in subjects’
understanding and acceptance of the questionnaire.
A rationality test was included in the questionnaire to determine
the understanding of the questionnaire by each subject. The
rationality test was a choice set of which one screening option was
logically preferred over the other option given the levels of each
test characteristic (biennial FS screening resulting in 40% RR
against biennial FS screening resulting in 70% RR). It is common
practice to exclude irrational responses (Weston and Fitzgerald,
2004; Ryan et al, 2005; Langenhoff et al, 2007), and we therefore
adopted this approach. However, some recent discussions in the
literature suggest that these responses could be included (Lancsar
and Louviere, 2006; Ryan et al, 2009). Furthermore, sensitivity
analyses were conducted and inclusion of irrational responses led
to similar results.
Subjects’ social economic status (SES), previous lower endoscopy
experience (sigmoidoscopy or colonoscopy) and experience with
CRC in family or close friends were determined. Furthermore, the
generic health status (EQ-5D summary score) was assessed. This is a
validated classification of subject’s own health (Dolan, 1997).
We conducted a pilot study (n¼20) to ascertain that subjects
could manage the length of the questionnaire and to evaluate
subjects’ understanding, acceptance and face validity of the
questionnaire, and the background information on the three
screening tests (Table A2). The questionnaire was mailed to all
subjects. Background information on the three screening tests was
printed on the first page of the questionnaire (Table A2). A
reminder was sent to non-responders 4 weeks later.
Data analysis
Each choice between two tests and the opt-out was considered as a
specific observation. The DCE was analysed using multinomial
logit regression models with test-specific parameters. The model
was implemented in SAS software (Version 9.1, SAS Institute). A
priori we expected the test and the two characteristics to be
important for subjects’ choices and that a higher RR value and
lengthening of ‘screening interval’ would have a positive effect on
preferences.
We assumed that there was no linear relationship between the
different levels of the characteristics. Therefore, we estimated the
following models for the DCE:
UFOBT ¼VFOBT þ eFOBT
¼b0 þ b1 Interval1yrþb2 Interval3yr
þb3 RR25þb4 RR40þeFOBT
UFS ¼VFS þ eFS
¼b5 þ b6 Interval5Yr þ b7Interval10Yr
þb8RR50 þ b9RR70 þ eFS
UTC ¼VTC þ eTC
¼b10 þ b11 Interval5Yr þ b12Interval10yr
þb13RR85 þ b14RR95 þ eTC
Unotest ¼ 0
Utility (U) represents the preference for a (hypothetical) CRC
screening programme. Utility consists of the deterministic and
observable component (V) and the random component (e) of the
analysis, accounting for unobserved or unobservable components
of choice. The observed utility (V) in this study is referred to as
preference (V). The absolute value of V has a relative interpreta-
tion: the higher the value of V, the stronger a respondent’s
preference for a particular screening strategy. The constant terms
(screening test; b0, b5 and b10) are alternative specific constants
that indicate the general attitude of subjects towards screening
with a specific screening test compared with no screening. b1,2,
Table 1 Alternatives, attributes and the alternative specific levels based on the literature
Alternatives Alternative specific levels Literature References
Screening interval (year)
FOBT 1/3–1–3 1–2 (Frazier et al, 2000; Levin et al, 2008)
Sigmoidoscopy 1–5–10 5–10 (Levin et al, 2008; Frazier et al, 2000)
Colonoscopy 2–5–10 5–10 (Frazier et al, 2000; Levin et al, 2008)
Risk reduction (%)
FOBT 10–25–40 13–33 (Kronborg et al, 1996; Hardcastle et al, 1996;
Kewenter et al, 1994; Mandel et al, 1993)
Sigmoidoscopy 40–50–70 49–62 (Selby et al, 1992; Zauber et al, 2008;
Newcomb et al, 1992; Muller and Sonnenberg,
1995; Hoff et al, 2009)
Colonoscopy 75–85–95 80–84 (Winawer et al, 1993; Zauber et al, 2008)
Abbreviation: FOBT¼faecal occult blood test.
Table 2 Subjects’ characteristics
Screening-
naive
subjects
Previously
screened
subjects P-value
Analysable subjects 400 496
Sex (male; n (%)) 209 (52) 260 (52) 0.96
Age (mean (s.d.)) 60.7 (6.6) 61.1 (6.4) 0.36
EQ5D score (mean (s.d.)) 0.94 (0.11) 0.93 (0.10) 0.76
Social economic status (n (%)) o0.01
High 195 (49) 196 (40)
Intermediate 77 (19) 96 (19)
Low 128 (32) 204 (41)
Lower endoscopy experience (n (%)) o0.01
Yes 92 (23) 242 (49)
No 307 (76) 251 (50)
Unknown 1 (1) 3 (1)
Knowing someone affected by CRC (n (%)) 0.78
Yes 53 (13) 67 (13)
No 285 (71) 381 (77)
Unknown 62 (16) 48 (10)
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sb6,7, and b11,12 are coefficients of the levels of the test characteristic
‘screening interval’ and b3,4, b8,9, and b13,14 are coefficients of the
levels of the test characteristic ‘risk reduction of CRC related
mortality’; each coefficient indicates the relative weight individuals
place on that test specific level compared with the reference level
for that test-specific test characteristic (for reference levels see
Table 3). A two-sided P-value smaller than 0.05 was considered to
be statistically significant.
Generic health status was dichotomised to an EQ-5D summary
score of ‘1’, representing full health, versus an EQ-5D summary
score ‘o1’, indicating sub-optimal health. Aggregate data on SES
were available at the level of the area postal code (www.cbs.nl) of
the subject, weighted by population size and classified into three
groups (high, intermediate and low).
Chi-square and Student’s t-tests were used to assess the
differences in the value of characteristics between screening-naive
and screened subjects, as well as among subgroups (age, gender,
SES, EQ-5D, prior endoscopy experience or knowing someone
affected by CRC) within the screening-naive population.
To examine the predicted uptake of CRC screening based on our
results, we applied previously proposed models to our data (Hall
et al, 2002; Gerard et al, 2008). We also investigated the effect of
changing the characteristics, as identified by the results of our
multinomial logit model, on the expected uptake of CRC screening.
Ethical approval
The study was approved by the Institutional Review Board of the
Erasmus MC, University Medical Centre (MEC-2007–224).
RESULTS
A total of 489 out of 1498 (33%) screening-naive and 545 out of 769
(71%) previously screened subjects returned the questionnaire.
Screening-naive subjects were of higher SES than screened subjects
(Po0.001, Table 2). A higher proportion of screened subjects
previously underwent a lower endoscopy compared with screen-
ing-naive subjects (49 vs 23%; Po0.001). Among the subjects that
participated in the CRC screening trial, all (172 out of 172) FS
screenees and 22% (70 out of 324) of the screenees (those had
undergone a FOBT previously) underwent a lower endoscopy.
DCE
A significantly higher proportion of the previously screened
subjects (91%) passed the rationality test compared with the
screening-naive subjects (82%; Po0.001).
Screening-naive subjects did not prefer FOBT over no screening.
They expressed a positive attitude towards FS and TC (positive and
statistically significant sign; Table 3; Figure 2). A high RR was
preferred over intermediate and low RR for all screening tests
(P-values o0.01). Screening-naive subjects expressed a more
positive attitude towards an intermediate (FOBT: annually; FS: 5
yearly; TC: 5 yearly) compared with a short screening interval
(FOBT: 4 monthly; FS: annual; TC: biennial). Further lengthening
of the screening interval (FOBT: triennial; FS: 10 yearly; TC: 10
yearly) had only a small positive effect on subjects’ preferences for
FOBT (P¼0.02) and FS (P¼0.02), and no effect on subjects’
preferences for TC screening.
Table 3 Regression coefficients from the discrete choice experiments for the different tests and attributes
Attribute levels
Screening-naive subjects
Coefficient (95%CI)
Previously screened subjects
Coefficient (95%CI) P-value
w
Screening test (base level ‘no screening’)
No screening (reference level)
FOBT  0.18 ( 0.44;0.08) 0.38 (0.15;0.62)* o0.001
Sigmoidoscopy 0.30 (0.06;0.54)* 0.94 (0.72;1.16)* o0.001
Colonoscopy 0.33 (0.08;0.57)* 1.05 (0.84;1.27)* o0.001
Risk reduction of CRC-related mortality
FOBT
3–2.7% (RR 10%) (reference level)
3–2.4% (RR 25%) 0.19 ( 0.01;0.38) 0.17 (-0.01;0.34) 0.88
3–1.8% (RR 40%) 0.78 (0.54;1.02)* 0.65 (0.44;0.87)* 0.45
Sigmoidoscopy
3.0–1.8% (RR 40%) (reference level)
3.0–1.5% (RR 50%) 0.10 ( 0.09;0.29) 0.33 (0.16;0.50)* 0.08
3.0–0.9% (RR 70%) 0.65 (0.42;0.89)* 0.65 (0.44;0.86)* 0.97
Colonoscopy
3.0–0.8% (RR 75%) (reference level)
3.0–0.5% (RR 85%) 0.16 ( 0.03;0.35) 0.19 (0.02;0.36)* 0.79
3.0–0.1% (RR 95%) 0.40 (0.17;0.62)* 0.41 (0.20;0.61)* 0.95
Screening interval
FOBT
4 monthly (reference level)
Annual 0.73 (0.52;0.93)* 0.64 (0.44;0.83)* 0.50
Triennial 0.96 (0.72;1.20)* 0.67 (0.46;0.89)* 0.07
Sigmoidoscopy
Annual (reference level)
5 yearly 0.92 (0.74;1.11)* 0.55 (0.39;0.72)* o0.001
10 yearly 1.14 (0.91;1.37)* 0.56 (0.36;0.75)* o0.001
Colonoscopy
Biennial (reference level)
5 yearly 0.71 (0.52;0.90)* 0.56 (0.39;0.73)* 0.22
10 yearly 0.72 (0.48;0.95)* 0.42 (0.21;0.63)* 0.06
Abbreviations: CI¼confidence interval; CRC¼colorectal cancer; FOBT¼faecal occult blood test; RR¼risk reduction.
wP-value describes the difference between screening-
naive and previously screened subjects. *P-value o0.05 compared with the reference level.
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sPreviously screened subjects had a positive attitude towards all
screening tests (Po0.001). A high RR value was preferred over
intermediate and low RR for all screening tests, and an inter-
mediate screening interval was preferred over a short screening
interval (Table 3, Figure 2). Previously screened subjects did not
prefer an intermediate interval over a long interval for all screening
tests (FOBT: P¼0.67; FS: P¼0.99; TC: P¼0.10).
Screening-naive versus previously screened subjects
Previously screened subjects had a more positive attitude towards
all screening tests than screening-naive subjects (Table 3,
Po0.001). The differences in preferences regarding RR and
screening interval between screening-naive and screened subjects
were statistically not significant, except for preferences regarding
5- and 10-yearly FS screening. The more positive attitude of
screening-naive subjects towards longer screening intervals
(5 yearly Po0.001; 10 yearly Po0.001) indicated that screening-
naive subjects valued infrequent screening more positively than
screened subjects.
Differences in preferences between subgroups
No differences in preferences were found between men and
women, apart from a more positive attitude towards TC among
men (TC: P¼0.02). Men, in contrast to women, did prefer FS and
TC to no screening (men: FS: Po0.001; TC: Po0.001; women FS:
P¼0.07; TC: P¼0.84). Respondents’ age, SES and EQ-5D
summary score did not influence the attitude towards a screening
test, interval or RR. Subjects who reported to have a close friend or
family member with CRC expressed a more positive attitude
towards TC screening than subjects without (P¼0.01). Experience
with FS or TC was positively associated with the willingness to
undergo a TC (Po0.001). Subjects that underwent FS screening
had a more positive attitude towards FS and TC screening than
subjects who performed a FOBT (Po0.001).
Trade-offs
Screening-naive subjects were, when assuming the same interval
(annual) and RR (40%), more willing to undergo FOBT than FS
screening (preference/observed utility (V) FOBT: V¼1.32; FS:
V¼0.30; Po0.001). Preferences were similar for a 5-yearly FS and
an annual FOBT if both tests would generate a RR of 40% (FOBT:
V¼1.32; FS: V¼1.23; P¼0.40). A 5-yearly FS was preferred to
annual FOBT if FOBT was associated with a less favourable RR
than FS screening (FOBT 25% RR: V¼0.73; FS 40% RR: V¼1.23;
Po0.001).
A 5-yearly FS was preferred to a 10-yearly TC if the difference in
RR was 25% in favour of TC (e.g. FS: RR 50%; TC: RR 75%;
Po0.001). The preferences for a 5-yearly FS and a 10-yearly TC
were similar if TC would achieve an additional 35% RR (P¼0.24),
whereas more than 45% difference in RR was associated with a
preference for 10-yearly TC (e.g. FS: RR 50%; TC: RR 95%;
Po0.001).
Screening-naive subjects equally preferred FS and TC screening,
but did prefer both endoscopic screening options over FOBT
screening if, based on the literature, the most realistic screening
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CRC related mortality reduction
Previously screened subjects
*
*
Colonoscopy Sigmoidoscopy
FOBT Colonoscopy Sigmoidoscopy
10% 40% 25%
10% 40% 25%
75% 95% 85%
75% 95% 85%
40% 70% 55%
40% 70% 55%
Figure 2 Preferences for the different screening strategies at a long (–––), intermediate (---) and short (—) screening interval and different levels of
mortality risk reduction for screening-naive and previously screened subjects. FOBT=faecal occult blood test; CRC=colorectal cancer. *Preferences for long
and intermediate screening interval were similar.
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sintervals and mortality reduction were applied (annual FOBT RR
25%: V¼0.73; 5-yearly FS RR 50%: V¼1.33; 10-yearly colono-
scopy RR 85%: V¼1.22 ; FS vs FOBT Po0.001; TC vs FOBT
Po0.001; TC vs FS P¼0.24).
Screened subjects made similar trade-offs between the screening
test, interval and RR as screening-naive subjects.
Predicted uptake
Predicted uptake of screening-naive subjects for FOBT, FS and TC
screening was 45, 58 and 58, respectively, assuming screening with
the reference level for RR and screening interval. On the basis of
realistic screening intervals and mortality reduction from the
literature, these numbers were 68% for FOBT, 79% for FS and 77%
for TC. The screening programme characteristics had substantial
impact on the expected uptake among screening-naive subjects
(Figure 3).
DISCUSSION
Principle findings
In this population-based study, we observed that the type of
screening test, screening interval and RR of CRC-related mortality
significantly influenced individual preferences among screening-
naive and previously screened subjects in the target population
(aged 50–74 years). These data provide insight into the relative
importance the effect of screening interval and RR of CRC-related
mortality on preferences for the three most commonly used
screening tests. Both screened and screening-naive subjects
preferred FS and TC to FOBT screening if, based on the literature
the most realistic screening interval and RR on CRC-related
mortality were applied (annual FOBT with 25% RR; 5-yearly FS
with 50% RR; 10-yearly colonoscopy with 85% RR; Mandel et al,
1993; Winawer et al, 1993; Kewenter et al, 1994; Hardcastle et al,
1996; Kronborg et al, 1996; Faivre et al, 2004; Levin et al, 2008;
Hoff et al, 2009). This underlines the importance of adequate
information on those aspects of CRC screening to achieve
informed decision making by potential screenees.
Five studies investigated preferences in CRC screening using a
DCE (Gyrd-Hansen and Sogaard, 2001; Salkeld et al, 2003; Marshall
et al, 2007; Hawley et al, 2008; Howard and Salkeld, 2008), with two
studies investigating preferences among available screening tests
(Marshall et al, 2007; Hawley et al, 2008). This is the first DCE
including both a screening-naive and previously screened popula-
tion. In agreement with previous DCE studies, we found that RR
dominated preferences for a screening test. Both FS and TC screening
were therefore preferred over FOBT screening when associated with
sufficient RR (Marshall et al, 2007; Hawley et al, 2008).
The literature on preferences for the optimal screening interval
per test is limited. One study reported a preference for 5 or 10
yearly to annual screening irrespective of the screening test
(Hawley et al, 2008). However, deciding on screening interval
without information on the screening test leads to unrealistic
choices, as an annual FOBT is less burdensome than an annual TC.
We therefore used test-specific screening intervals that add to the
validity of our results. In our study, previously screened subjects
equally preferred intermediate and long screening interval for all
tests. Reassurance may be a reason for preferring frequent
screening (Cantor et al, 2002). However, both intermediate and
long interval of all three screening tests were preferred over a short
interval, suggesting that subjects trade-off between reassurance
and frequency of undergoing a screening test.
Men had a more positive attitude towards FS and colonoscopy
screening than women. This finding is in accordance with FS
screening programmes that described a lower uptake among women
than among men (Segnan et al, 2002; UK Flexible Sigmoidoscopy
Screening Investigators, 2002; Hol et al, 2009a). Known barriers for
women to participate in endoscopy screening are male endoscopists
(Menees et al, 2005) and anxiety before screening (Farraye et al,
2004). A different approach to inform both sexes on screening or
sex-specific screening strategies might be considered in a nation-
wide screening programme to improve acceptance.
The results of this study may be relevant to predict population
preferences for newer screening tests with a similar profile or an
improved version of a screening test. For example, recently
randomised trials demonstrated more favourable detection rates
for FIT than gFOBT (van Rossum et al, 2008; Hol et al, 2009b),
suggesting a larger reduction of CRC-related mortality. According
to our data, informing people in the target population about a more
+16%
+5%
+19%
+18%
+23%
+3%
+15%
+20%
+23%
+4%
+9%
+16%
25% 20% 15% 10% 5% 0%
FOBT
+25%
+40%
Annual
Triennial
Sigmoidoscopy
+50%
+70%
5-yearly
10-yearly
Colonoscopy
+85%
+95%
5-yearly
10-yearly
Reference level: RR +10%, four monthly screening intervals
Reference level: RR +40%, annual screening
Reference level: RR +75%, biennial screening
Increase in uptake (%)
Figure 3 Effects of changing the screening programme characteristics on the average probability of uptake for, respectively, FOBT (45%), FS (58%) and
TC (58%) in screening-naive subjects.
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higher acceptance of FIT screening and most likely a higher uptake.
Predicted uptake of FS or TC screening based on our model was
significantly higher than uptake of FOBT screening, given realistic
levels. This finding is in contrast to the observed higher uptake of
FOBT than FS screening in the randomised screening trial
performed in the same population as this DCE. Screenees in this
trial were, however, not specifically informed on test efficacy. This
suggests that increasing awareness on the efficacy of a screening
test may enhance uptake. It is therefore of paramount importance
to improve the level of awareness on achievable risk reduction of
CRC-related mortality to obtain a higher uptake, especially for the
more effective endoscopic screening tests. This is further under-
lined by two European studies. A Swiss study (Marbet et al, 2008),
in which the majority (75%) of all screenees chose to undergo a
TC, and only a small proportion (25%) preferred FOBT or FS
screening after they were informed about the efficacy of the three
screening tests. A large population-based Italian study found
similar participation rates for FS and FOBT when subjects were
offered a choice between both strategies (Segnan et al, 2005).
Strengths and weaknesses of this study
In contrast to previous DCE studies, we used a labelled instead of an
unlabelled DCE design. In a labelled design, the specific screening
test is mentioned in each choice option (FOBT, FS and TC;
Table A1), whereas in an unlabelled design the screening test is
presented as ‘screening test ‘A’, ‘B’ or ‘C’ and is further described by
certain characteristics that are presented in the choice set. CRC
screening tests may evoke individual feelings that cannot be
described in a questionnaire (e.g. anxiety for an endoscopy). It is
therefore difficult to adequately convey the essential differences from
a subject’s perspective between FOBT and endoscopic tests in terms
of, for example, ‘more burdensome’ or ‘less burdensome’. Using a
labelled design, scenarios are more realistic, which adds to the
validity of the results. Furthermore, we assessed preferences among
screening-naive and screened subjects within the target population
(aged 50–74years), including all social economic classes that add to
the generalisability of the results. Experienced subjects stated a more
positive attitude towards all screening tests than screening-naive
subjects. A selection bias may explain this difference in attitude, as
experienced subjects have already demonstrated interest in screening
and therefore express a more positive attitude towards screening.
There is, however, also an experience effect, that is, anticipated
discomfort and pain might be higher than actually experienced. This
experience might reduce anticipated pain and discomfort for
successive screening round. In addition, there may also be an
expose effect, that is, people tend to develop a preference merely
because they are familiar with it. Our results suggest that subjects
who underwent screening are willing to return for a successive
screening round that is of vital importance for the efficacy of a
screening program. Costs of screening were not included as a test
characteristic in this study. All CRC screening programs in Europe,
including the Netherlands, do not require out-of-pocket costs.
Including cost would therefore influence the results in an unrealistic
manner. A limitation of this study is the significantly lower response
rate in screening-naive than in previously screened subjects. This
may have led to selection bias. Non-respondents may have a more
negative attitude towards screening than respondents. Our results
may therefore reflect a more positive attitude than that exists in the
general population as a whole. The method of framing the levels of
risk reduction may have influenced our results. However, we
minimised the framing effect in accordance to the literature by
presenting absolute values in the questionnaire (Edwards et al, 2002).
It is common practice to exclude irrational responses from the
analysis (Weston and Fitzgerald, 2004; Ryan et al, 2005; Langenhoff
et al, 2007), and that was why this approach was adopted here. Ryan
et al (2009) recently postulated that researchers should be cautious
when excluding respondents, who failed the rationality test.
Additional information on respondents’ considerations for failing
the rationality test is required. The usage of a ‘think aloud technique’
in the group of subjects who failed the rationality test to determine
truly irrational responses has been suggested (Lancsar and Louviere,
2006; Ryan et al, 2009). Further research on the effects of excluding
subjects based on additional information on failing the rationality
test is needed to adopt this approach as common practice.
CONCLUSIONS
These data provide insight into the extent by which interval and
RR of CRC-related mortality affect preferences for CRC screening
tests in the experienced and screening-naive subjects. Both
screening-naive and previously screened subjects stated a more
positive attitude towards both endoscopic screening strategies than
FOBT if, based on the literature, the most realistic screening
interval and RR on CRC-related mortality were applied. The RR
value of CRC-related mortality determined preferences for
endoscopic screening. This underlines the importance of aware-
ness on achievable RR of CRC-related mortality of the different
screening test to enhance uptake particularly for endoscopic
screening tests and to optimise informed choice.
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sTable A1 Choice set
Appendix
Table A2 Background information on all screening test as applied to all subjects
Faecal occult blood test Sigmoidoscopy Colonoscopy
Preparation None. - One or two enemas (bowel preparation).
- No fasting.
- You have to drink 4l of special cleansing
solution the day before the procedure.
- You have to fast for 12h before the
procedure.
- You cannot work the afternoon before and
the day of the procedure.
The procedure How do I carry out the test?
At home, you collect a small amount of
faeces of 1–3 bowel movements using a
test set (see picture). You can return the
test by mail to the laboratory.
What does the test measure?
The test measures whether there are
(in)visible traces of blood present in the
stools.
What happens if the test results
are abnormal?
You will be advised to undergo a
colonoscopy.
The procedure
The last 60cm of the large bowel is examined
by using a flexible tube with a small camera on
the tip. This tube is inserted through the anus.
During the procedure the large bowel will be
filled with air to carefully examine the bowel.
What do I feel of the investigation?
Because of the air put into your bowel you
may feel abdominal cramps.
What happens if abnormalities are
found?
Precursors of colon carcinoma (polyps) are
removed during the procedure (this is painless).
You will be advised to undergo a colonoscopy
to see whether there are other abnormalities
in the remainder large bowel.
The procedure
You will be given conscious sedation (‘short
narcosis’). Therefore, you may fall into a light
sleep. The entire large bowel (100-120cm) is
examined by using a flexible tube with a small
camera on the tip. This tube is inserted through
the anus. During the procedure the large bowel
will be filled with air in order to carefully
examine the bowel.
What do I feel of the investigation?
Due to the air and tube in your bowel you may
feel abdominal pressure and cramps.
What happens if abnormalities are
found?
Precursors of colon carcinoma (polyps) are
removed during the procedure (this is painless).
After the procedure - You can return to your daily activities
immediately.
- You may eat and drink again immediately
and go home.
- You may eat and drink again and go home
after one hour.
- You cannot drive a car, ride a motorcycle or
bicycle.
Perceived burden Low. High. High.
Results - You will receive the result by mail within 2
weeks.
- Directly after the procedure.
- When tissue has been removed, you will
receive the pathology results by mail
within 2 weeks.
- Directly after the procedure.
- When tissue has been removed, you will
receive the pathology results by mail within
2 weeks.
Test at home or in
the hospital
At home. Hospital. Hospital.
Total duration of the
procedure
30min. 15min. 1h and 45min.
Complications Never. In 1 in 10,000 individuals: severe blood
loss or a perforation or a tear through
the bowel wall.
In 1 in 1000 individuals: severe blood loss or a
perforation or a tear through the bowel wall.
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